Published in Vaccine Weekly, December 31st, 2003
The additional contract and amendments to the first contract will provide ID Biomedical with approximately US$4.5 million for further process development and manufacturing activities related to producing a subunit recombinant plague antigen under current good manufacturing practices. This second contract brings DVC's approximate total funding commitment to ID Biomedical to up to US$10.6 million for this program.
The plague, also known as "the Black Death," is caused by...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly